Xencor (XNCR) Projected to Post Earnings on Thursday

Xencor (NASDAQ:XNCR) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Xencor to post earnings of ($0.64) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 4, 2026 at 9:30 AM ET.

Xencor Stock Performance

NASDAQ:XNCR opened at $11.81 on Wednesday. The business’s fifty day moving average is $13.33 and its 200 day moving average is $12.74. The firm has a market cap of $843.35 million, a price-to-earnings ratio of -6.67 and a beta of 0.98. Xencor has a 52-week low of $6.92 and a 52-week high of $18.69.

Analyst Ratings Changes

A number of equities analysts have recently commented on XNCR shares. Cantor Fitzgerald raised their price objective on shares of Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Royal Bank Of Canada upped their price objective on Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Truist Financial started coverage on shares of Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 target price on the stock. Finally, Barclays lifted their target price on shares of Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Xencor has a consensus rating of “Moderate Buy” and a consensus target price of $24.88.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 73,367 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares in the company, valued at $3,718,943.28. This represents a 23.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.71, for a total value of $1,796,862.67. Following the completion of the sale, the chief executive officer directly owned 466,635 shares of the company’s stock, valued at $7,330,835.85. The trade was a 19.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Xencor

Several hedge funds and other institutional investors have recently modified their holdings of XNCR. Tower Research Capital LLC TRC raised its stake in Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. purchased a new position in shares of Xencor during the 2nd quarter worth approximately $79,000. Norges Bank bought a new position in shares of Xencor in the 4th quarter worth approximately $175,000. Prelude Capital Management LLC bought a new position in shares of Xencor in the 3rd quarter worth approximately $139,000. Finally, Entropy Technologies LP purchased a new position in shares of Xencor in the 4th quarter valued at approximately $183,000.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.